Patents by Inventor Marc Lapierre

Marc Lapierre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100249109
    Abstract: The present invention relates to substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted tetrahydropyrazolo-pyrido-azepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: March 31, 2010
    Publication date: September 30, 2010
    Applicant: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Rui-Yang Yang, Nivedita Namdev, Jeffrey S. Link
  • Publication number: 20100239525
    Abstract: The present invention relates to substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 30, 2009
    Publication date: September 23, 2010
    Applicant: ArQule, Inc.
    Inventors: Syed M. Ali, Mark A. Ashwell, Sudharshan Eathiraj, Eugene Kelleher, Jean-Marc Lapierre, Yanbin Liu, Nivedita Namdev, Rocio Palma, Manish Tandon, David Vensel, Neil Westlund, Hui Wu, Rui-Yang Yang
  • Publication number: 20100183600
    Abstract: The present invention provides imidazooxazole and imidazothiazole compounds and their syntheses. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.
    Type: Application
    Filed: December 4, 2009
    Publication date: July 22, 2010
    Applicant: ARQULE, INC.
    Inventors: Jean-Marc Lapierre, Yanbin Liu, Manish Tandon, Mark A. Ashwell
  • Publication number: 20100172867
    Abstract: The present invention relates to substituted 1H-pyrazolo-[3,4-d]pyrimidine-6-amine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted 1H-pyrazolo-[3,4-d]pyrimidine-6-amine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds and pharmaceutical compositions to subjects in need thereof.
    Type: Application
    Filed: December 30, 2009
    Publication date: July 8, 2010
    Applicant: ArQule, Inc.
    Inventors: Syed M. Ali, Mark A. Ashwell, Jason Hill, Jean-Marc Lapierre, Magdi Moussa, Nivedita Namdev, Robert Nicewonger, Manish Tandon, Rui-Yang Yang
  • Publication number: 20090226395
    Abstract: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified ?-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as ?-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.
    Type: Application
    Filed: May 1, 2009
    Publication date: September 10, 2009
    Applicant: ArQule, Inc.
    Inventors: Mark A. Ashwell, Chiang J. Li, Manish Tandon, Yanbin Liu, Jean-Marc LaPierre, Zhiwei Jiang
  • Publication number: 20090176801
    Abstract: The invention provides lapachone analogs and derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of cancer or precancerous conditions.
    Type: Application
    Filed: October 16, 2008
    Publication date: July 9, 2009
    Applicant: ArQule, Inc.
    Inventors: Mark Ashwell, Manish Tandon, Jean-Marc Lapierre, Syed Ali, Yanbin Liu, Chiang J. Li
  • Publication number: 20090136499
    Abstract: The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.
    Type: Application
    Filed: January 20, 2009
    Publication date: May 28, 2009
    Applicant: ARQULE, INC.
    Inventors: Jean-Marc Lapierre, Nivedita D. Namdev, Mark A. Ashwell, Dennis S. France, Hui Wu, Patrick M. Hutchins, Manish Tandon, Yanbin Liu, Jeff S. Link, Syed M. Ali, Chris J. Brassard, Robb B. Nicewonger, Anton Filikov, Rebecca J. Carazza
  • Publication number: 20090111985
    Abstract: An efficient route for the synthesis is of formula (I) of imidazooxazole and imidazothiazole inhibitors of the p38 MAP kinase pathway, useful as therapeutics for disease conditions including inflammation and auto-immune responses is described.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 30, 2009
    Inventors: Mark A. Ashwell, Manish Tandon, Jean-Marc Lapierre
  • Publication number: 20090105166
    Abstract: The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as ?-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).
    Type: Application
    Filed: August 21, 2007
    Publication date: April 23, 2009
    Inventors: Mark A. Ashwell, Manish Tandon, Jean-Marc Lapierre, Syed Ali, David Vensel, Chiang J. Li
  • Patent number: 7501430
    Abstract: The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: March 10, 2009
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Nivedita D. Namdev, Mark A. Ashwell, Dennis S. France, Hui Wu, Patrick M. Hutchins, Manish Tandon, Yanbin Liu, Jeff S. Link, Syed M. Ali, Chris J. Brassard, Robb B. Nicewonger, Anton Filikov, Rebecca J. Carazza
  • Patent number: 7354931
    Abstract: The current invention provide novel heterocyclic retinoid compounds, methods of treating or preventing chronic obstructive pulmonary disease, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of these disorders and methods for delivering formulations of these retinoids to a mammal having these disorders.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: April 8, 2008
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20070281955
    Abstract: The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAFV600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.
    Type: Application
    Filed: April 16, 2007
    Publication date: December 6, 2007
    Inventors: Jean-Marc Lapierre, Nivedita Namdev, Mark Ashwell, Dennis France, Hui Wu, Patrick Hutchins, Manish Tandon, Yanbin Liu, Jeff Link, Syed Ali, Chris Brassard, Robb Nicewonger, Anton Filikov, Rebecca Carazza
  • Publication number: 20060035963
    Abstract: The present invention relates to quinone prodrug compositions and therapeutic methods using such prodrug compositions. Preferably, the quinone compounds of the invention are napthoquinone compounds such as ?-lapachone or ?-lapachone analogs. The quinone prodrug compositions of the invention exhibit improved solubility, stability, bioavailability, and pharmacokinetic properties, as well as improved plasma half-life in vivo.
    Type: Application
    Filed: August 11, 2005
    Publication date: February 16, 2006
    Inventors: Mark Ashwell, Manish Tandon, Jean-Marc Lapierre, Yanbin Liu
  • Publication number: 20060034796
    Abstract: The present invention relates to polymer-modified quinone-containing and carbonyl-containing therapeutic agents, including polymer-modified ?-lapachone compounds, and methods of treating cancer by administering the polymer-modified therapeutic agents to a subject. Polymer-modification of therapeutic agents, such as ?-lapachone compounds, provides effective transport of polymer-modified therapeutic agents to tumor cells or tumor tissues by exploiting the EPR effect in tumor tissues.
    Type: Application
    Filed: August 11, 2005
    Publication date: February 16, 2006
    Inventors: Mark Ashwell, Chiang Li, Manish Tandon, Yanbin Liu, Jean-Marc LaPierre, Zhiwei Jiang
  • Patent number: 6940463
    Abstract: An ultra-wideband antenna for operating in a frequency is disclosed wherein a monopole antenna extends from a ground plane. The monopole has an effective length L of one quarter wavelength at the lowest frequency f1. A dielectric resonator antenna (DRA) surrounds the monopole antenna for resonating at substantially between or at two and three times the lowest frequency f1, the DRA is of a height of less than ¾ L and is disposed in such a manner as being above the ground plane and either contacting or spaced therefrom by a gap G, wherein 0?G?0.2 H. The ultra-wideband antenna is of a much greater bandwidth than the sum of bandwidth of the monople or the DRA alone.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: September 6, 2005
    Assignee: Her Majesty the Queen in Right of Canada, as represented by the Minister of Industry, through the Communications Research Centre Canada
    Inventors: Apisak Ittipiboon, Aldo Petosa, Soulideth Thirakoune, David Lee, Marc Lapierre, Yahia Autar
  • Publication number: 20050113447
    Abstract: This invention relates to new RAR selective retinoid agonists of formula I wherein the symbols are as defined in the specification to their pharmaceutically acceptable salts, individual isomers or to a racemic or non-racemic mixture; to pharmaceutical compositions containing them, and to methods for their use as therapeutic agents.
    Type: Application
    Filed: November 2, 2004
    Publication date: May 26, 2005
    Inventors: Paula Belloni, Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20050049238
    Abstract: The current invention provide novel heterocyclic retinoid compounds, methods of treating or preventing chronic obstructive pulmonary disease, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of these disorders and methods for delivering formulations of these retinoids to a mammal having these disorders.
    Type: Application
    Filed: October 7, 2004
    Publication date: March 3, 2005
    Inventors: Michael Klaus, Jean-Marc Lapierre
  • Publication number: 20050017903
    Abstract: An ultra-wideband antenna for operating in a frequency is disclosed wherein a monopole antenna extends from a ground plane. The monopole has an effective length L of one quarter wavelength at the lowest frequency f1. A dielectric resonator antenna (DRA) surrounds the monopole antenna for resonating at substantially between or at two and three times the lowest frequency f1. the DRA is of a height of less than ¾ L and is disposed in such a manner as being above the ground plane and either contacting or spaced therefrom by a gap G, wherein 0?G?0.2 H. The ultra-wideband antenna is of a much greater bandwidth than the sum of bandwidth of the monople or the DRA alone.
    Type: Application
    Filed: July 24, 2003
    Publication date: January 27, 2005
    Inventors: Apisak Ittipiboon, Aldo Petosa, Soulideth Thirakoune, David Lee, Marc Lapierre, Yahia Autar
  • Patent number: 6844466
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 18, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Paula Nanette Belloni, Denis John Kertesz, Michael Klaus, Jean-Marc Lapierre
  • Patent number: 6838472
    Abstract: The current invention provide novel compounds, methods of treating or preventing emphysema, cancer and dermatological disorders, pharmaceutical compositions suitable for the treatment or prevention of emphysema, cancer and dermatological disorders and methods for delivering formulations into the lung of a mammal suffering from emphysema, cancer and dermatological disorders.
    Type: Grant
    Filed: September 17, 2002
    Date of Patent: January 4, 2005
    Assignee: Syntex (U.S.A.) LLC
    Inventors: Michael Klaus, Jean-Marc Lapierre